Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20330026 | 0.88 | SLC6A4 (0.33) | CYP4F2CYP4A11FFAR4MTNR1AMTNR1B | |
| SCHEMBL21421631 | 0.88 | SLC6A4 (0.33) | CYP4F2CYP4A11FFAR4MTNR1AMTNR1B | |
| SCHEMBL20046523 | 0.87 | CYP4F2 (0.30) | CYP4F2CYP4A11 | |
| SCHEMBL21025855 | 0.86 | ADRB2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL20133408 | 0.86 | ADRB2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL20330464 | 0.84 | GCK (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL21906890 | 0.81 | RORC (0.32) | MTNR1AMTNR1B | |
| SCHEMBL18612324 | 0.81 | RORC (0.32) | MTNR1AMTNR1B | |
| SCHEMBL24788958 | 0.81 | IAPP (0.37) | CYP4F2CYP4A11FFAR4MTNR1AMTNR1B | |
| SCHEMBL20443306 | 0.80 | CYP4F2 (0.38) | CYP4F2CYP4A11FFAR4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604506-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | CYP4F2 3279/4885CYP4A11 3593/4885FFAR4 3395/4885 |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CYP4F2 2577/4885CYP4A11 2702/4885FFAR4 4098/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CYP4F2 2100/4885CYP4A11 553/4885FFAR4 2061/4885 |
| US-20220388984-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CYP4F2 2577/4885CYP4A11 2702/4885FFAR4 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.